Q-omics provides the consensus-scored SNX31 profile across patient tissues and cancer cell-line models. SNX31 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNX31 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SNX31 RNA expression shows 13,569 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where SNX31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX31 survival associations across molecular data types. SNX31 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX31 RNA expression–survival associations across cancer types. High SNX31 expression shows unfavorable associations in KIRP and ACC, but favorable associations in HNSC, SCLC, THCA and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for SNX31 RNA expression.
This table summarizes SNX31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNX31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX31 shows lower tumor expression in HNSC, BRCA, UCEC and PRAD and higher tumor expression in LUSC and LUAD. The HNSC box plot shows higher SNX31 RNA expression in normal versus tumor tissue (log2 FC = −2.015, t-test p < 0.001).
This table shows molecular features associated with SNX31 in patient tissues and cancer cell lines. In patient samples, SNX31 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and URINARY_TRACT.
